Benzinga | Aug 2, 2021 04:31PM EDT

Ultragenyx Pharmaceutical Q2 EPS $(1.81) Misses $(1.36) Estimate, Sales $86.97M Beat $85.03M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.36) by 33.09 percent. This is a 61.61 percent decrease over losses of $(1.12) per share from the same period last year. The company reported quarterly sales of $86.97 million which beat the analyst consensus estimate of $85.03 million by 2.29 percent. This is a 40.94 percent increase over sales of $61.71 million the same period last year.